“Today’s announcement underscores the confidence we have in our corporate strategy to drive long-term sustainable growth and build shareholder value,” said
Under the program, the company may purchase its shares from time to time in the open market or in privately negotiated transactions. The number of shares repurchased and the timing of the purchases will depend on a number of factors, including share price, trading volume and general market conditions, along with working capital requirements, general business conditions and other factors. The company may also from time to time establish a trading plan under Rule 10b5-1 of the Securities and Exchange Act of 1934 to facilitate purchases of its shares under this authorization.
AMAG had approximately 34.7 million shares of common stock outstanding as of
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA) and other federal securities laws. Any statements contained herein which do not describe historical facts, including, among others, AMAG’s plans for and the impact of the share repurchase program, including the effect on shareholder value and AMAG’s growth; AMAG’s belief that the share repurchase program is a strategic use of capital; AMAG’s ability to actively pursue acquisitions and to make strategic investments to generate profitable growth; expectations regarding AMAG’s corporate strategy; and plans to expand and diversify AMAG’s portfolio are forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those discussed in such forward-looking statements.
Such risks and uncertainties include, among others, those risks identified in AMAG’s filings with the
AMAG disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.
AMAG Pharmaceuticals® is a registered trademark of
Linda LennoxVice President, Investor Relations 617-498-2846